A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor

We aimed to identify the clinical variables associated with a better glucose-lowering response to the sodium glucose cotransporter 2 inhibitor ipragliflozin in people with type 2 diabetes mellitus (T2DM). We especially focused on urinary glucose excretion (UGE). This was a single-arm multicenter pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, You-Cheol, Kim, Jae Hyeon, Lee, Byung-Wan, Lee, Woo Je
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Diabetes Association 2019
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943269/
https://www.ncbi.nlm.nih.gov/pubmed/31237132
http://dx.doi.org/10.4093/dmj.2018.0257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943269/
https://www.ncbi.nlm.nih.gov/pubmed/31237132
http://dx.doi.org/10.4093/dmj.2018.0257

Ejemplares similares